Evidence map›Paper›PMID 8757876›Full record

ArticleInfection and immunity1996

Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans.

T R Kozel, L C Weinhold, D M Lupan

Abstract read
In one paragraph

Article in Infection and immunity, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Frontiers in immunology · 2020
    Review
  3. Article
  4. Review
  5. Article
  6. Canadian clinical practice guidelines for invasive candidiasis in adults.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2010
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

T R KozelDepartment of Microbiology and Cell and Molecular Biology Program, University of Nevada, Reno 89557, USA.
L C Weinhold
D M Lupan

Funding

PHOSPHOMANNOPROTEIN ADHESIN AS A VACCINE CANDIDATEP01AI037194 · NIAID · LA BIOMED RES INST/ HARBOR UCLA MED CTR · PI EDWARDS, JOHN E. · 1995 to 2003
$3.6M
Cryptococcal polysaccharide-phagocytosis inhibitionR01AI014209 · NIAID · UNIVERSITY OF NEVADA RENO · PI KOZEL, THOMAS R · 1985 to 2009
$1.9M
CRYPTOCOCCAL POLYSACCHARIDE--PHAGOCYTOSIS INHIBITIONR37AI014209 · NIAID · UNIVERSITY OF NEVADA RENO · PI KOZEL, THOMAS R · 1995 to 2004
$1.5M
NIAID NIH HHS AI 14209NIAID NIH HHS AI 37194
6 · The paper itself

Abstract

Candida albicans is a potent activator of the complement system. The objective of this study was to characterize factors that influence the kinetics for activation of C3 and binding of C3 fragments to C. albicans. Factors that were examined included the surface properties of the yeast and contributions of the classical and alternative complement pathways. The results showed that incubation of hydrophobic, hydrophilic, or germinating yeast cells in normal human serum (NHS) containing radiolabeled C3 led to immediate accumulation of C3 on all three cell types, although the rate of accumulation of C3 on germinating cells was lower. An examination of the sites for early C3 binding showed that classical pathway initiation led to immediate, synchronous binding over the entire cell surface. A blockade of the classical pathway by absorption of putative classical pathway initiators or by chelation of calcium limited activation to the alternative pathway. Binding of C3 solely via the alternative pathway was characterized by a significant lag in the initial binding kinetics. In the absence of classical pathway initiation, the early cellular sites for C3 binding appeared as random, asynchronous foci of C3 that appeared to expand with time. The factor(s) mediating rapid deposition of C3 that was characteristic of the classical pathway initiation was reciprocally cross-absorbed by hydrophilic and hydrophobic C. albicans but was not removed by absorption of NHS with Saccharomyces cerevisiae, encapsulated Cryptococcus neoformans, or nonencapsulated C. neoformans. Delayed binding of C3 produced by absorption of serum was largely reversed by addition to the absorbed serum of immunoglobulin G isolated from NHS, indicating a significant role for a naturally occurring anti-C. albicans immunoglobulin C. in classical pathway initiation.

Indexed as

Complement Pathway, AlternativeAntibodies, FungalBinding SitesBloodCandida albicansComplement C3Complement Pathway, ClassicalCryptococcus neoformansHumansImmunoglobulin GKineticsProtein BindingSaccharomyces cerevisiaeSpecies SpecificityAntibodies, FungalComplement C3Immunoglobulin G

Identifiers

PMID8757876
PMCPMC174230

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.